*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**MicroTech Medical (Hangzhou) Co., Ltd.**
**微泰醫療器械(杭州)股份有限公司**
*(A joint stock company incorporated in the People's Republic of China with limited liability)*
**(Stock code: 2235)**

# VOLUNTARY ANNOUNCEMENT
# OVERSEAS APPROVAL OF THE COMPANY'S CONTINUOUS GLUCOSE MONITORING SYSTEM

This announcement is published by MicroTech Medical (Hangzhou) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis, for the purpose of keeping the shareholders and potential investors of the Company informed of the latest development of the Group.

LinX Continuous Glucose Monitoring System The board (the "**Board**") of directors (the "**Directors**", and each a "**Director**") of the Company is pleased to announce that Our LinX (the international brand name of AiDEX X) continuous glucose monitoring system has recently received market approval in Brazil, which is indicated for continuous glucose monitoring in both adults and children.

As a core market in Latin America, Brazil boasts substantial market potential. According to the data released in the 2025 IDF Diabetes Atlas by the International Diabetes Federation ("**IDF**"), there are approximately 16.62 million people aged 20–79 years old living with diabetes in Brazil, with a prevalence rate of 10.7%, ranking sixth globally in terms of the number of patients. In 2024, Brazil's diabetes-related healthcare expenditure reached approximately USD45.1 billion, ranking third globally, only behind the United States and China.

The approval of the LinX Continuous Glucose Monitoring System for marketing in Brazil will significantly strengthen the Company's market presence in Latin America, laying a solid foundation for the scaled expansion of its international business and revenue growth. Going forward, the Company will continue to focus on the global development of diabetes monitoring, treatment and management solutions, and persistently drive technological and product innovation in related fields.

**The Company reminds the investors that the production, sales and the resulting income of the above-mentioned product are affected by many factors such as market changes. Shareholders and potential investors of the Company are requested to exercise caution when dealing with the shares of the Company.**

By order of the Board
**MicroTech Medical (Hangzhou) Co., Ltd.**
**Zheng Pan**
*Chairman of the Board*

Hangzhou, the PRC, December 23, 2025

*As at the date of this announcement, the executive Directors of the Company are Dr. Zheng Pan, Dr. Yu Fei, Dr. Shi Yonghui and Ms. Liu Xiu; the non-executive Directors of the Company are Mr. Mao Shuo and Ms. Gao Yun; and the independent non-executive Directors of the Company are Dr. Li Lihua, Ms. Wang Chunfeng, Mr. Ho Kin Cheong Kelvin and Dr. Cheng Hua.*